PLZF-RARα direct target genes
| Enriched biofunction . | No. of genes . | P . | Gene . | ES . | Fold change . |
|---|---|---|---|---|---|
| Hematologic system development/function | 214 | .001 | |||
| Movement of myeloid cells/homing/chemotaxis | 69 | .001 | ITGB2 | 4.7 | −1.8 |
| CSF2RA | 1.4 | −1.8 | |||
| CTSG | 1.5 | −3.5 | |||
| PTPN6 | 2.5 | −3.3 | |||
| LSP1 | 2.1 | −1.8 | |||
| AZU1 | 2.2 | −2.5 | |||
| Differentiation of leukocytes, phagocytes, mononuclear leukocytes, macrophages | 77 | .001 | CD1D | 3.2 | −3.7 |
| ID1 | 3.1 | −2.9 | |||
| CEBPϵ | 3.9 | −7 | |||
| IL8 | 7 | −17 | |||
| EGR1 | 1.5 | −10.6 | |||
| RUNX1 | 7.1 | −1.7 | |||
| TGFB1 | 1.5 | −1.9 | |||
| Cell cycle | 191 | .001 | |||
| Cell division: arrest in cell division | 170 | .001 | CDKN2D | 2.7 | +4.2 |
| CDKN1B | 4.2 | +2.4 | |||
| CDKN1C | 1.6 | +1.8 | |||
| MXD1 | 1.7 | +3.2 | |||
| c-Myc | 1.9 | −11 | |||
| BCL2L1 | 2.6 | +1.6 | |||
| BCL6 | 1.9 | +1.8 | |||
| ITGB1 | 3.1 | +2.2 | |||
| Cell death | 362 | .001 | |||
| Apoptosis of myeloid cells/granulocytes/ hematopoietic cells | 283 | .001 | MCL1 | 1.9 | +1.8 |
| NFE2L2 | 1.8 | +1.5 | |||
| CD44 | 1.9 | +2.6 | |||
| PTEN | 3.8 | +2.1 | |||
| BCL2L1 | 2.6 | +1.6 | |||
| MXD1 | 1.7 | +3.2 | |||
| MPL | 1.9 | +18 |
| Enriched biofunction . | No. of genes . | P . | Gene . | ES . | Fold change . |
|---|---|---|---|---|---|
| Hematologic system development/function | 214 | .001 | |||
| Movement of myeloid cells/homing/chemotaxis | 69 | .001 | ITGB2 | 4.7 | −1.8 |
| CSF2RA | 1.4 | −1.8 | |||
| CTSG | 1.5 | −3.5 | |||
| PTPN6 | 2.5 | −3.3 | |||
| LSP1 | 2.1 | −1.8 | |||
| AZU1 | 2.2 | −2.5 | |||
| Differentiation of leukocytes, phagocytes, mononuclear leukocytes, macrophages | 77 | .001 | CD1D | 3.2 | −3.7 |
| ID1 | 3.1 | −2.9 | |||
| CEBPϵ | 3.9 | −7 | |||
| IL8 | 7 | −17 | |||
| EGR1 | 1.5 | −10.6 | |||
| RUNX1 | 7.1 | −1.7 | |||
| TGFB1 | 1.5 | −1.9 | |||
| Cell cycle | 191 | .001 | |||
| Cell division: arrest in cell division | 170 | .001 | CDKN2D | 2.7 | +4.2 |
| CDKN1B | 4.2 | +2.4 | |||
| CDKN1C | 1.6 | +1.8 | |||
| MXD1 | 1.7 | +3.2 | |||
| c-Myc | 1.9 | −11 | |||
| BCL2L1 | 2.6 | +1.6 | |||
| BCL6 | 1.9 | +1.8 | |||
| ITGB1 | 3.1 | +2.2 | |||
| Cell death | 362 | .001 | |||
| Apoptosis of myeloid cells/granulocytes/ hematopoietic cells | 283 | .001 | MCL1 | 1.9 | +1.8 |
| NFE2L2 | 1.8 | +1.5 | |||
| CD44 | 1.9 | +2.6 | |||
| PTEN | 3.8 | +2.1 | |||
| BCL2L1 | 2.6 | +1.6 | |||
| MXD1 | 1.7 | +3.2 | |||
| MPL | 1.9 | +18 |
PLZF-RARα direct target genes identified by comparison of ChIP-chip and gene expression arrays (1672 genes). PLZF-RARα binding to target promoters (ES) represents the average of ChIP-chip peak enrichment for at least 2/3 biologic replicates. PLZF-RARα–mediated gene expression changes are represented as the average fold change of biologic triplicates.
− indicates down-regulated; and +, up-regulated.